Response Rate as an Endpoint in Clinical Trials
نویسندگان
چکیده
منابع مشابه
Response rate as an endpoint in clinical trials.
JNCI Vol. 99, Issue 2 | January 17, 2007 been changing somewhat in recent years for treatments without direct cytotoxic effects. In designing clinical trials in a specifi c disease that involve the assessment of objective response, several questions should be asked, and the existing evidence bearing on the answers to those questions should be assessed before deciding on how response rate as an ...
متن کاملDurable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials
BACKGROUND Traditional response criteria may be insufficient to characterize full clinical benefits of anticancer immunotherapies. Consequently, endpoints such as durable response rate (DRR; a continuous response [complete or partial objective response] beginning within 12 months of treatment and lasting ≥6 months) have been employed. There has not, however, been validation that DRR correlates ...
متن کاملSustained clinical response as an endpoint in treatment trials of Clostridium difficile-associated diarrhea.
Occurrence of diarrhea following initially successful treatment l i i s a major shortcoming in the treatment of Clostridium difficile-associated diarrhea (CDAD). Sustained response is a clinical endpoint proposed to account for differences among treatment agents with respect to a combination of initial response/cure and recurrence. Until recently, vancomycin was the only FDA-approved treatment ...
متن کاملBeyond dyspnoea as an endpoint in acute heart failure trials.
Acute heart failure syndromes (AHFS) has been defined as new onset or recurrence of gradually or rapidly worsening signs and symptoms of heart failure (HF) necessitating urgent or emergency therapeutic intervention. The number of hospitalizations for AHFS continues to increase and they account for 1 million admissions annually in both Europe and the USA. Dyspnoea is the most common presenting s...
متن کاملOverview: progression-free survival as an endpoint in clinical trials with solid tumors.
Progression-free survival (PFS) is increasingly used as an important and even a primary endpoint in randomized cancer clinical trials in the evaluation of patients with solid tumors for both practical and clinical considerations. Although in its simplest form, PFS is the time from randomization to a predefined endpoint, there are many factors that can influence the exact moment of when disease ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: JNCI: Journal of the National Cancer Institute
سال: 2007
ISSN: 1460-2105,0027-8874
DOI: 10.1093/jnci/djk024